Shahab Ghafghazi, MD
Cardiovascular Disease · Louisville, KYNPI 1316195274
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (59.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Abbott at 38.6% of the total. 2025 is the largest year on record at $5,310, more than ten times the $519 reported in 2019.
Across 88 payments — averaging $111.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Pfizer$2K
- Philips North America LLC$2K
- Janssen Research & Development, LLC$1K
- Abiomed$575
- Boston Scientific$155
- plus $639 from 14 others
Across 43 payments — averaging $9167.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$165K
- Boehringer Ingelheim International GmbH$69K
- Cleerly, Inc.$46K
- Boehringer Ingelheim Pharma GmbH & Co.kg$46K
- Livanova USA, Inc.$32K
- Janssen Research & Development, LLC$32K
- plus $6K from 1 others
What the payments were for
- Speaking & faculty fees$1,72017%
- Travel & lodging$5,80259%
- Food & beverage$2,31023%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 29 | $3,796 |
| Pfizer | 1 | $1,720 |
| Philips North America LLC | 7 | $1,518 |
| Janssen Research & Development, LLC | 10 | $1,429 |
| Abiomed | 3 | $575 |
| Boston Scientific | 8 | $155 |
| Boehringer Ingelheim | 5 | $102 |
| Cardiovascular Systems Inc. | 7 | $94 |
| Impulse Dynamics (USA) Inc. | 1 | $85 |
| Osprey Medical Inc | 3 | $68 |
| Cleerly, Inc. | 1 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Inari Medical, Inc. | 2 | $46 |
| Medtronic | 2 | $32 |
| Amgen | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Novartis | 1 | $18 |
| Elutia, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRICLIP$3,203
- VYNDAQEL$1,720
- (9520) IGT Devices Undivided$1,477
- Impella$575
How this compares
$9,832 in reported general payments places this provider in the 85th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 35 | $49,373 |
| EliquisApixaban | 37 | $40,083 |
| FarxigaDapagliflozin Propanediol | 42 | $37,403 |
| XareltoRivaroxaban | 22 | $33,641 |
| OzempicSemaglutide | 24 | $25,471 |
| MounjaroTirzepatide | 24 | $24,807 |
| EntrestoSacubitril/Valsartan | 11 | $19,224 |
| BrilintaTicagrelor | 30 | $15,453 |
| Repatha SureclickEvolocumab | 20 | $12,474 |
| TrulicityDulaglutide | 12 | $10,813 |
| VascepaIcosapent Ethyl | 22 | $7,213 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $5,208 |
| Varenicline Tartrate | 19 | $4,798 |
| Bumetanide | 27 | $1,583 |
| Metoprolol Succinate | 132 | $1,574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $102 | $49,37335 claims |
| PfizerEliquis | $1,720 | $40,08337 claims |
| Johnson & JohnsonXarelto | $16 | $33,64122 claims |
| NovartisEntresto | $18 | $19,22411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Louisville
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- John HarrisLouisville$129K
- Rohan SamsonLouisville$94K
- Vipul PanchalLouisville$39K
- Steven RaibleLouisville$30K
- Chandhiran RangaswamyLouisville$19K
- Joseph LashLouisville$16K
- Shanker ChandiramaniLouisville$16K
- Pradeep SinghLouisville$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.